Lineage Cell Therapeutics (LCTX) Misses Q3 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Lineage Cell Therapeutics (LCTX) Misses Q3 EPS by 6c

Lineage Cell Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

November 12, 2019 4:05 PM EST

New Data from Phase I/IIa Clinical Study of OpRegen® Presented at 2019 AAO Meeting; All Cohort 4 Patients Have Better Visual Acuity as of Last Visit Implemented Significant Additional Cost-Cutting Measures to Reduce Budget for 2020 Received CE Mark Approval for Renevia®; Working to Identify European Commercial Partner Conducted Sales of 6.25 Million Shares of OncoCyte Corporation for $10.7 Million in Net Proceeds Strengthened Extensive IP Portfolio with the Issuance of 3 New U.S. Patents Awarded Additional NIH Grant for Innovative Vision Restoration Program

CARLSBAD,... More